Friday 28 April 2017

Vascular Graft Market Worldwide Market Shares, Strategies, and Forecasts 2014 to 2023

Vascular surgical procedure remains often invasive and needs prolonged hospital stays. Conventional vascular surgery comprises of opening the body, cutting vessels, and closing it by means of sutures, it consist of procedures such as carotid endarterectomy, open abdominal aneurysm repair and lower extremity bypass surgery. In contrast, majority of vascular graft procedures are usually are minimally invasive besides involve repairing vessels from inside. Catheter-based devices are introduced through a minor incision and are directed with the aid of real-time imaging technologies. Typical endovascular procedures comprises of stenting, angioplasty, stent-grafting, and atherectomy.
Vascular graft is a medical procedure that is done to redirect the flow of blood in an area of the body and is generally performed due to the insufficient blood flow and as a part of organ transplantation. In general, a person’s own vein is chosen as a graft material or other synthetic materials such as Dacron, ePTFE or a different person's vein are also generally used. Moreover, can also be redirected and serve as vascular grafts. An ideal vascular graft consist of the following characteristics such as appropriate size to match the host vessels, rapid healing, ease of handling, increased porosity, resistance to infection, low thrombogenicity and economical
The global vascular graft market is segmented based on types, products, application and geography. The vascular grafts are of various types such as autologous, preserved autologous and synthetic. The autologous includes saphenous veins and radial artery; preserved autologous includes cryopreserved veins, whereas the synthetic grafts consist of PTFE, Teflon and Dacron. The PTFE has gained more popularity over Dacron due to the better tissue adhesion, improved pliability and lack of requirement to preclot prior to implantation. The products include endovascular stent graft, peripheral vascular graft, hemodialysis access graft and coronary artery bypass graft. The endovascular stent graft is known to have a largest market share in this segment due to high volume of EVAR (endovascular aortic repair) procedures. The applications include cardiovascular diseases, kidney failure, vascular occlusion, aneurysm, diabetes and others.
Based on the geography, market segmentation is North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominates the vascular graft market due to the presence of advanced healthcare infrastructures, reimbursement policies and adoption of new innovative products. However, Asia Pacific is expected to be the fastest growing in the vascular graft market due to the government initiatives and fast development in the research facilities.
 Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11096
Some of the factors such as rise in the healthcare expenditures, increasing demand of minimally invasive procedures, increase in the prevalence of cardiovascular diseases, ageing population are some of factors responsible to drive the global vascular graft market. However, sometime the failure of the products and alternative therapies acts as a restrain or hinders the growth of the market. The rise in the unhealthy lifestyle of the people and reimbursement policies in the developed nations will create an opportunity to vascular graft market.
Some of the key players in the vascular graft market are Medtronic Plc., Bard Peripheral Vascular Inc., W.L. Gore & Associates, Inc., Cook Medical, LeMaitre Vascular Inc. Humacyte, Inc. and Terumo Medical Corporation, and B. Braun.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
 Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453

Posted by at No comments:
Labels:

ECG Systems Market – Global Industry Analysis Report, 2016 - 2024

Global ECG Systems Market: Description
 Electrocardiography (ECG) is a way of measuring the electrical activity of the heart. During each heartbeat, cardiac muscles undergo depolarization, creating a small electrical charge. This charge, the frequency and magnitude of which serves as a sign of heart health, is detected via electrodes on the chest and limbs. ECG systems allow cardiologists to diagnose several cardiac conditions, such as arrhythmias, congenital cardiac problems, and poor blood supply. The ease of conducting an ECG test has led to it becoming widely used for primary cardiologic diagnosis.
 Global ECG Systems Market: Drivers
 The primary driver for the global ECG systems market is the increasing prevalence of cardiovascular diseases. The increasing acceptance of the Western lifestyle in developing regions such as Asia Pacific and Latin America has led to an increasing prevalence of lifestyle disorders such as diabetes and obesity, which are major risk factors for cardiovascular diseases. Cardiac diseases are already among the deadliest groups of diseases across the world and are expected to increase in morbidity in the coming years due to the increasingly sedentary lifestyle of the modern populace. This will likely propel the global ECG systems market at a brisk pace.
 Steady technological innovation in medical devices, required to iron out the tiniest of flaws and make vital medical devices as precise as possible, has led to the development of advanced ECG systems that monitor cardiac activity with a high degree of precision. This has made diagnosis through ECG systems increasingly reliable, consequently increasing patient confidence and thus driving the global ECG systems market.
 Several governments across the world have been proactive in establishing advanced, modernized health-care networks. This has led to steady government support for the development of disease monitoring devices that can provide accurate diagnoses and thus help reduce the incidence of diseases. This has worked in favor of the global ECG systems market in the past few years and is expected to remain an influential factor in the coming years.
 Global ECG Systems Market: Restraints and Opportunities
 On the flip side, the instability of economic conditions in many parts of the world and the lack of promising reimbursement policies are the major restraints on the global ECG systems market. The ECG systems market has also suffered from saturation in developed economies, where healthcare networks have already reached a high level of sophistication. However, the rising demand for ECG systems from emerging countries will help market players overcome this concern.
 The ECG systems market remains highly competitive at present, with many companies able to offer devices at similar levels of technological sophistication. Collaboration for R&D as well as other parts of the product lifecycle has thus emerged as a major opportunity for players in the global ECG systems market. Collaboration will help players improve their R&D channels, while M&As will also allow multinational players to expand their geographical reach. Major players in the global ECG systems market include Royal Philips Healthcare, Nihon Kohden Corp., Welch Allyn, GE Healthcare, and Medtronic.
 Global ECG Systems Market: Regional Dynamics
 The global ECG systems market was dominated by North America in 2015. The high prevalence of lifestyle disorders such as diabetes and obesity is a major factor responsible for the dominance of North America in the global ECG systems market. The increasing aging population, which is more prone to cardiac trouble than younger demographics, is another key factor expected to shape the trajectory of the ECG systems market in the region. The Europe market for ECG systems took up the second-largest share in the global market.
 The future of the global ECG systems market, though, is expected to be dominated by Asia Pacific, with the increasing prevalence of cardiac disorders and increasing government support in APAC countries expected to help the regional market post strong figures in the coming years.
 The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
 The study is a source of reliable data on: 
  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis
The regional analysis covers: 
  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
 A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
 Highlights of the report: 
  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market
 Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453

Posted by at No comments:
Labels:

Empty Capsules Market Trends & Forecast up to 2023

Global Empty Capsules Market: Overview
 The demand for capsules is growing on account of the mounting consumption of medicines worldwide. This trend augurs well for the global empty capsules market, where growth has thus far been driven by the demand for both nongelatin and hard gelatin capsules. The changing demographics of the world have necessitated the greater production of medicines to treat various kinds of diseases. Capsules, being among the most versatile forms of administering drug doses, are thus expected to be consumed in larger volumes over the next few years.
 The typical capsule is made from gelatin and encloses either a single medicinal ingredient or a combination of the same. Empty capsules are available in numerous sizes depending on the dosage of medicine to be administered. The use of gelatin to make capsules is most widespread because the material renders several advantages, including but not limited to better stability in various temperature ranges, its odorlessness and tastelessness, and softness, which makes it easy to swallow. However, the market also features capsules made of other nongelatin-based materials.
 Obtain Report Details: http://www.transparencymarketresearch.com/empty-capsules-market.html
 The demand for empty capsules is expected to rise substantially in the years ahead thanks largely to the overall growth and expansion of the global pharmaceuticals industry. Moreover, the greater demand for nutraceuticals will also provide the global capsules market an opportunity to expand as several food supplements and functional foods are encapsulated to make them convenient for on-the-go consumption.
 Global Empty Capsules Market: Trends, Drivers, and Restraints
 Because capsules are regarded as a convenient method of consuming health supplements and medication, their demand is likely to grow substantially. Moreover, consumers in developing regions now have higher spending power and thus the ability to allocate more funds toward healthcare and preventative healthcare. Besides the pharmaceuticals and nutraceuticals industries, the demand for encapsulated ingredients is also on the rise in the cosmetics and cosmeceuticals sector. These end-user trends will have a far-reaching influence on the growth of the global empty capsules market.
 Although there is no dearth of revenue-generation opportunities in the global empty capsules market, companies will have to brave headwinds in the form of tightening regulatory guidelines and the need for a high initial investment in R&D and manufacturing facilities. Furthermore, in mass markets such as India, where the majority of vegetarian consumers view animal-derived gelatin in a negative light, companies will face the need to find solutions around the problem by focusing more on nongelatin capsules. Overall, globally, the demand for soft gelatin capsules is showing a clear increase, and players are recommended to explore growth avenues in this space.
 Request for Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1674
 Global Empty Capsules Market: Region-wise Outlook
 The demand for empty capsules is seen to be highest in regions where the pharmaceuticals sector is well developed. Thus, while the developed countries of the west have been the traditional markets for empty capsules, the growing number of pharmaceutical contract research establishments in Asian countries will lead to an increased demand for empty capsules.
 The North America empty capsules market leads in terms of revenue share and the outlook for the Asia Pacific empty capsules market remains positive. Europe follows North America in terms of revenue in the global empty capsules market. A number of companies in the empty capsules market are increasingly moving eastward, causing a shift in the market’s dynamics.
 Companies that currently rake in the highest revenue in the global empty capsules market are ACG Worldwide, Capsugel, Medi-Caps Ltd, Qualicaps, Inc., CapsCanada Corporation, Bright Pharma Caps, Inc., Suheung Co. Ltd, and Snail Pharma Industry Co. Ltd.
 Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
Posted by at No comments:
Labels:

Growing Trends in Immunotoxins Market

Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting recombinant protein is the most common method for manufacturing a substance for clinical trial. The insoluble protein is washed thoroughly with detergent to remove solublized, endotoxin, denatured, and condensed in guanidine-dithioerythritol solution. Then the recombinant protein is restored as a denatured protein or also known as renatured protein by rapid intensity into redox buffer containing glutathione and arginine, and the dialyzed renatured protein purified by sizing chromatography and anion exchange.
Toxins used in immunotoxin structures are derived from fungi, bacteria and plants, while most function by inhibiting protein synthesis. The bacterial toxins that are commonly used in immunotoxins include the toxin from Pseudomonas exotoxin (PE) and Diphtheria toxin (DT). Ribosomes inactivating proteins (RIPs) gelonin, the A chain of ricin (RTA), pokeweed antiviral protein and dodecandron are included in plant toxins that are utilized in immunotoxins. As it is an enzyme, one toxin molecule can work on many substrate molecules, having a lethal effect on the cell. Immunotoxin’s use in haematological malignancies is considered to be very important, which are characterized by a high percentage of malignant cells that express the target antigen in contrast to solid tumours, which are characterized by a mixed cell population, and cells that are often not easily accessible for immunotoxin.
According to a research, cancer was observed as the most frequent cause of death in most of the developed countries. In the U.S., the estimated number of new cancer cases was above 1.5 million in 2010, with a mortality rate accounting for 23% of total deaths. Thus, cancer is observed to be the major application of immunotoxin, to use highly potent agents as a cancer therapy, it is necessary to target the killing agent selectively to the cancer cells and immunotoxin therapy is also considered to be an important and effective molecular cancer treatment strategy. The major driver of immunotoxins market is increasing global prevalence of cancer. For instance, according to World Health Organization (WHO) in 2012, Cancers figure among the leading causes of death worldwide, accounting for 8.2 million deaths while lung, liver, stomach, colorectal and breast cancers cause the most cancer deaths each year. It is also expected that annual cancer cases will rise from 14 million in 2012 to 2022 within the next two decades.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10241
Major advantages of immunotoxins are minimum toxicity in normal tissues and discerning cytotoxicity towards tumor cells. The immunotoxin’s clinical development in the treatment of solid tumors has been impeded in part, by the initiation of an immune response directed mainly against the toxin moiety, and in part by loss of activity of the fusion protein, e.g. by sterical barrier in the case of large toxin moieties. Strategies to overcome these limitations and develop the clinical performance of immunotoxins may reduce immunogenicity of it by removing the T-cell epitopes and use bispecific or bivalent constructs as next generation molecules.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Posted by at No comments:
Labels:

Home Health Care Market Responds to Impressive Progress in Medicine and Healthcare

A new study by Transparency Market Research (TMR), titled “Home Health Care Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024,” states that the increasing base of geriatric population and the rising incidence of chronic diseases are boosting the market significantly.
In addition to this, the emergent technical advancements in the field of home healthcare and the growing demand for highly effective yet cost-efficient healthcare delivery systems are expected to propel this market during the forecast period. However, the rising concerns over patients’ safety, consistent changes in reimbursement policies, and insufficient insurance coverage options are likely to hamper the growth of this market in the coming years, notes the research study.
The report studies the global home healthcare market on the basis of the product, service, delivery mode, and the region. Based on product, the market has been categorized into mobility care products, testing, monitoring, and screening products, and therapeutic products. Among these, the demand for testing, monitoring, and screening products is rising significantly.
Further, the study has classified the mobility care products segment into cranes, crutches, walkers, mobility scooters, and wheelchairs. The testing, monitoring, and screening products segment has been classified into heart monitoring systems, peak flow meters, blood pressure monitors, pulse oximeters, HIV test kits, and ovulation and pregnancy kits. Oxygen delivery systems, ventilators, nebulizers, wound care products, inhalers, insulin delivery devices, and dialysis devices have been identified as the main therapeutic products available in the home healthcare market.
Based on service, the report has segmented the worldwide home healthcare market into rehabilitation services, infusion therapy services, unskilled care services, respiratory therapy services, pregnancy care services, skilled care services, and palliative care and hospice. The infusion services segment is likely to gain significant impetus from the increasing demand for these services over the forecast period.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10292
By delivery mode, the market has been categorized into cloud-based home healthcare, web-based home healthcare, and on-premise home healthcare. Among these, the cloud-based segment is projected to dominate the global market over the forecast period.
Region-wise, the report has segmented the global market for home healthcare into North America, Asia Pacific, Europe, and the Rest of the World.
A&D Co. Ltd., Apria Healthcare Group Inc., Almost Family Inc., Abbott Laboratories, Amedisys Inc., Fresenius Se & Co. KGaA, General Electric Co., Kindred Healthcare Inc., Kinnser Software Inc., LHC Group Inc., Linde Group, Mckesson Corp., Omron Corp., Philips Healthcare, and  Roche are some of the key players operating in the home healthcare market, states the research report.
Posted by at No comments:
Labels:

Thursday 27 April 2017

Anti-snoring Devices and Snoring Surgery Market - Latest Trends & Insights 2024

The leading companies operating in the anti-snoring devices and snoring surgery market have been focusing on product innovation and miniaturization of sleep apnea devices. This is a novel trend swaying the global anti-snoring devices and snoring surgery market. Integrated by the nanotechnology, this trend could be a major determinant for the market’s growth. Currently, the market is exhibiting a strong focus on innovation, as per a new study by Transparency Market Research. Efforts by new and existing players have resulted in the development of an impressive pipeline of products that are expected to help find better cure for people suffering from sleep apnea.
 Read Full Report: http://www.transparencymarketresearch.com/antisnoring-devices-and-snoring-surgery-market.html
 Q: What strategies are the leading market players adopting to gain stronghold?
 A: The global anti-snoring devices and snoring surgery market is marked by the presence of an increasing number of companies which has rendered its vendor landscape highly competitive and fragmented. TMR finds that enterprises such as Medtronic plc, Philips Healthcare, GE Healthcare, Fisher & Paykel Healthcare, and ResMed, Inc are not only leading market participant but also hold significant share in the global market with their robust geographic reach and extensive product portfolio.
 Of these, Medtronic has managed emerging dominant in the overall market following a slew of recent acquisitions. Medtronic along with Phillips Healthcare and GE healthcare are the top players in the market, contributing a whopping 93.69% of the overall revenue generated by the market. In order to accelerate their pace of gains, a majority of the leading companies operating in the anti-snoring devices and snoring surgery market are investing in research and development activities.
 Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6910
 Besides this they are also focusing on product innovation to strengthen their position in the market. For instance, an Australian company has recently launched a 3D printed anti-snoring device that can be customized based on an individual’s need. The medical device company is called Oventus Medical and is based in Melbourne, Australia. It is set to manufacture a device they named O2Vent. It is a lightweight titanium devices and can help patients stop snoring by delivering air to the back of his or her mouth. Such innovations hold great promise of the company success in the market
 Q: Which region will offer most lucrative opportunities to the market?
 A: North America and Europe together dominated the global anti-soring devices and snoring surgery market in 2015. While these are mature markets, the opportunities existing in Asia Pacific is also expected to prove quite lucrative for companies manufacturing anti-snoring devices. Because the region is characterized by presence of unmet medical needs and high patient pool it is expected to attract several of the small or medium scale companies and new entrants looking to establish their footprint in the market. In addition favorable government initiatives to spread awareness about sleep apnea and its possible treatments will also support the market’s strong growth in Asia Pacific.

Posted by at No comments:
Labels:

Cone Beam Computed Tomography Market: Worldwide Market Shares, Strategies, and Forecasts 2015 to 2023

According to a new market report published by Transparency Market Research “Cone Beam Computed Tomography (CBCT) Market (Application – Dental Implants, Orthodontics, Oral Surgery, Endodontics, and General Surgery): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015–2023”, the global CBCT market was valued at US$ 407.5 Mn in 2014 and is anticipated to expand at a CAGR of 10.0% from 2015 to 2023 to reach US$ 960.8 Mn by 2023.
 Information related to diagnosis is vital for valid decision of a treatment plan in dentistry. Precise images lead to a better treatment plan and improved results. CBCT is an evolving technology suitable for dental images and maxillofacial structures. It can provide the most relevant clinical data compared to conventional imaging methods such as radiographs. The introduction of CBCT technology in dentistry has changed the diagnostic landscape rapidly allowing dental professionals to diagnose in three dimensions. CBCT systems are now preferred to conventional systems for advantages such as lower radiation dose to patients, smaller acquisition times for the resolution required in dentistry, and affordable cost option to medical CT, and improved resolution with more details.
 Read Full Report: http://www.transparencymarketresearch.com/cone-beam-computed-tomography-market.html
 Disorders prevalent among adult patients such as periodontal diseases, tooth loss, endodontically restored teeth, restored teeth and trauma sequelae, and coexisting with malocclusion are driving demand for various dentistry applications. Demand for orthodontic treatment in adults has increased significantly over the past few years with the need for detailed diagnosis. In orthodontics, CBCT helps in visualization of impacted teeth, identification of root resorption, ankylosis and dentoalveolar fracture, evaluation of height and bone volume, examination of temporomandibular joint and upper airway, accurate determination of bone-tooth inconsistencies in non-erupted teeth, and diagnosis of pathologies. Moreover, increasing accessibility of this technology helps dentists by providing three-dimensional representation of the maxillofacial skeleton with nominal distortion.
 Based on application, the global cone beam computed tomography (CBCT) market has been segmented dental implants, orthodontics, oral surgery, endodontics, and general dental surgery. Geographically, the market has been analyzed for five regions: North America, Europe, Asia Pacific, Latin America, and Rest of the World. The CBCT market is driven by increasing demand for applications in dentistry across the globe. North America held the largest share of the CBCT market in 2014, followed by Europe. The largest market share of North America is attributed to increasing geriatric population and growing demand for advanced technology products for dental imaging in the U.S. According to statistics provided by the American Association of Oral and Maxillofacial Surgeons (2014), about 100,000 to 300,000 dental implants are placed each year. However, due to the industry’s failure to offer lower cost, conservative dentistry took a downturn during the recession.
 Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10508
 Europe is a lucrative market for CBCT. Germany continues to lead the market in innovative invisible braces and demand for these orthodontic systems. Asia-Pacific was identified as the third largest market for CBCT in 2014. Demand has increased significantly in Asia due to rise in health care expenditures as well as disposable incomes of the population. Moreover, the market is driven by increase in population with oral diseases and disorders opting for advanced dental imaging techniques such as CBCT. The region is expected to register the fastest CAGR during the forecast period. Increasing awareness, disposable income, and government initiatives are driving the CBCT market in this region.
 In Latin America, Mexico and Argentina are believed to be revenue pockets for the CBCT market. The market in Mexico and Argentina is expected to grow at a considerable rate. Population growth, increasing health spending, chronic disease incidence, and new technology acquisition, particularly diagnostic equipment in the public sector, are factors contributing to the growth of the market in Mexico.
 Major players in this market are Cefla Group (Italy), Carestream Health (U.S.), Danaher Corporation (U.S.), QR s.r.l. (Newtom) (Italy), Planmeca OY (Finland), Prexion Inc. (U.S.), VATECH Global Co. Ltd. (South Korea), and Sirona Dental Systems (Germany).

Posted by at No comments:
Labels:

Nonalcoholic Steatohepatitis (NASH) Therapeutics Market to Reach US$20.27 bn by 2025, Elafibranor Projected to Spur Growth

According to a new market report published by Transparency Market Research “Nonalcoholic Steatohepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025”, the nonalcoholic steatohepatitis (NASH) therapeutics market is anticipated to expand at a CAGR of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.
Nonalcoholic Steatohepatitis (NASH) is a syndrome that advances in patients who are not alcoholic; it causes liver damage that is histologically indistinguishable from alcoholic hepatitis. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware of their liver problem. However, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and no longer able to work properly. It develops most frequently in patients with at least one of the following risk factors as obesity, dyslipidemia, and glucose intolerance. Pathogenesis is not clearly understood but seems to be linked to insulin resistance. Most of the patients are asymptomatic. Laboratory outcomes include elevations in aminotransferase levels. Biopsy is essential to confirm the diagnosis. Treatment mainly focusses on elimination of causes and risk factors.
The prevalence of NASH and NAFLD is increasing across the globe but it is more in developed regions such as North America. Both NASH and NAFLD are becoming more common, perhaps because of the greater number of Americans with obesity. In the past few years, the rate of obesity has almost doubled in adults and tripled in children. Obesity also adds to diabetes and high blood cholesterol, which can further complicate the health of people suffering from NASH. Diabetes and high blood cholesterol are also becoming more common among Americans.
Currently, no specific therapies exist for NASH treatment. The most important recommendations given to persons with this disease are weight reduction (if overweight), following a balanced and healthy diet, increasing physical activity, avoiding alcohol and avoiding unnecessary medications.
The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report enlists the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market and the market for Elafibranor is expected to grow at the highest CAGR. This growth is majorly due to Elafibranor which is considered to be the most advanced drug in this category.
Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.).

Posted by at No comments:
Labels:

Global Active Pharmaceutical Market Sees Rising Preference for Contract Manufacturing and Biologics

Active Pharmaceutical Ingredient (API) refers to a substance or substance combination used in manufacturing a drug product. The active pharmaceutical ingredient market has been categorized by manufacturing process, API type, drug type, therapeutic area and geography. Manufacturing processes in the global API market include captive and contract manufacturing. The captive API manufacturing segment comprises the active pharmaceutical ingredients produced for internal consumption of a pharmaceutical company. Captive manufacturing accounted for the highest market share in 2014, however the share of this market segment is expected to witness a decline due high degree of competition from contract manufacturing and reduced profitability and thus increased preference for outsourcing API production over captive production. Outsourcing production helps pharmaceutical companies focus on their core business of developing new drug products. Contract manufacturing is being preferred because of its advantage in terms of capital and labor costs, access to advanced manufacturing technologies, and benefits from the global distribution network.
The global active pharmaceutical market is segmented into API types: synthetic chemical API and biological API. The synthetic chemical API segment held the largest share of more than 70% of active pharmaceutical market in 2014. This market segment has evolved in the past few years due to innovations in the methods of synthesizing chemical APIs, which improves their stability and potency. The large volume of the demand is an important reason for the larger share of synthetic chemical API segment. On the other hand, the biological API market segment is expected to have the highest growth rate of 8.1% during the forecast period of 2015-2023. Large pharmaceutical companies are scaling down their small molecule manufacturing facilities to focus on biologic drugs, thereby presenting greater opportunities for contract manufacturing companies. The overall cost of drug development program for biologics is less as compared to chemical APIs, primarily because of high success rates in the pipeline phase. This factor has attracted higher investments in the biologics and biosimilars market.
Drug types in the global API market include branded prescription drug, generic prescription drug and OTC drugs. The branded API segment accounted for the largest share of 76% in the global API market in 2014. The factors driving the branded prescription drugs include government initiatives that has lowered the copayment on generics while raising it on the branded drugs. The increasing demand for biological drugs and supportive policies of the European Union toward biosimilars is also one of the major driving factors to boost branded API market. Moreover, the generic prescription drugs segment is expected to grow at the highest rate of 7.3% during the forecast period. With the rising cost of healthcare, governments and payers are pushing for the increasing generics consumption over branded drugs, thus driving growth of the generic APIs market. Over-the-counter (drugs) are considered sufficiently safe and effective for use without prescriptions from health care professionals and hence would continue to grow at a steady rate during the forecast period.
Based on the therapeutic area, the global API market is segmented into various disorders such as cardiovascular, metabolic, disorders, oncology, musculoskeletal, non-steroidal anti-inflammatory drugs (NSAIDs), and others. The cardiovascular disorder segment held the largest share of global active pharmaceutical ingredient market during the forecast period. Cardiovascular, metabolic, and neurological disorders held a combined market share of over 50% in 2014 due to the rising geriatric population, increasing prevalence of cardiovascular diseases, diabetes and neurological disease globally. Whereas, the oncology segment is expected to grow at the highest rate of 8.2% during the forecast period owing to the rising prevalence of cancer. The significant growth observed in oncology API has helped companies to prefer specialized manufacturing plants for oncology drugs. The musculoskeletal disorders, NSAIDs and other therapeutics area is anticipated to grow at a steady rate during the forecast period of 2015 to 2023.
Geographically, North America dominated the active pharmaceutical ingredient market in 2014 with a share of 35.1% owing to factors such as higher consumption of API due to the presence of major pharmaceutical companies in this region. Biologics have become one of the top-selling drugs in North America. Thus, the expected market entry of biosimilars with flexible regulatory process would further boost the API market in North America. Japan, China, India and South Korea, the leading pharmaceutical hubs in Asia are majorly responsible for almost 30% of the total market share placing the region at the second position in the world. Major factors driving the API markets in China and India are the availability of low cost production facilities and labor cost. Other factors driving the market in the region include the tax incentives, rising government expenditure on health care and government plans to restructure the fragmented industry. Europe accounted for a market share of 21.6% in 2014. The governments of various countries in Europe have started supporting the manufacture of generic drugs post the financial crisis. Patent expirations of major blockbuster drugs in Europe would fuel the growth of the API market in the near future. Demand for generic drugs is increasing not only in developed countries, but also in developing and underdeveloped countries in South America and Africa. Brazil and South Africa are the important centers of pharmaceutical manufacturing in this regional segment. Factors boosting the growth of the market in developing regions are cost-efficient manufacturing, large number of patients, rising demand for generic drugs, and improvement in the healthcare infrastructure.
Teva Pharmaceutical Industries Ltd dominated active pharmaceutical ingredients market in 2014. Major factors attributed to its dominance are broad product portfolio and high market penetration. Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd secured the second market position in 2015. North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. held the third position in 2015. Other players in the active pharmaceutical ingredients market include Dr.Reddy's Laboratories Limited, Sandoz (Novartis AG), Aurobindo Pharma Limited, Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. and others.
Posted by at No comments:
Labels:

Tourniquet Market: Rising Number of Road Accidents Uphold Need for Tourniquet Systems in Emergency Healthcare Services

According to a new market report published by Transparency Market Research “Tourniquet Market – (By Product – Tourniquet Systems, Tourniquet Cuffs; By Application – Arm Cuffs, Leg cuffs; By End-Users: Hospitals, Physician/Clinic, Non-institutional) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2015 – 2023” the global tourniquet market was valued at US$ 184.6 Mn in 2014 and is estimated to reach US$ 408.6 Mn by 2023 at a CAGR of 9.3% from 2015 to 2023.
 Tourniquet device is a medical equipment which checks excessive bleeding from the affected body part by compressing the blood vessels and nerves. Tourniquet has been identified as one of the most reasonable options for controlling hemorrhages. User-friendly design, durability and low cost are some of the prime factors which increases the demand for tourniquet devices in hospitals and clinics. Increasing incidence of orthopedic injuries, military war injuries, and growing hospital admissions for surgeries are boosting the growth of the tourniquet market.
 Read Full Report: http://www.transparencymarketresearch.com/pressrelease/tourniquet-market.htm
 The global tourniquet market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World, which are further categorized into various countries under each region. North America accounted for the largest market for the global tourniquet market in 2014. Dominance of North America has been attributed to increasing incidence of accidents which leads to serious limb injuries. The use of disposable tourniquet cuffs are on the rise in North America due to the product’s lower price and lesser risk of contamination. In addition, technological advancement associated with tourniquet system and cuffs would have a positive impact on the growth of the tourniquet market. North America comprises Canada and the U.S. North America was the largest market for tourniquet in 2014 primarily due to increasing incidence of road accidents leading to traumatic injuries and rapid introduction of advanced tourniquet devices. Furthermore, major players such as Zimmer Biomet and Stryker Corporation are based in North America. This is likely to boost market growth in the region.
 Europe is the second largest market for global tourniquet market in 2014 due to increasing geriatric population undergoing surgeries, high awareness about available tourniquet cuffs, and favorable reimbursement policies. Germany has the largest market share of Europe tourniquet market due to improved health care infrastructure and a developed medical technology market. Factors attributed to the rapid growth of the tourniquet market in Europe are growing trend toward adoption of disposable tourniquet cuffs and increasing incidence of traffic-related injuries, sports injuries, and occupational injuries. The forecast reveals that countries in rest of the Europe would expand at the fastest CAGR during the forecast period.
 Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=11627
 Asia Pacific was the third largest market for tourniquet devices in 2014, and is anticipated to grow at the highest CAGR during the forecast period. Emerging markets in Asia Pacific hold immense growth potential due to factors such as rise in road accidents, increase in the prevalence of limb surgeries, growing health care expenditure, and improving health care infrastructure. For instance, according to the Central Bureau of Health Intelligence (India), the number of government hospitals in India has increased since year 2000 which is a strong reason for promising growth of the market in Asia Pacific region. Growth in medical tourism and market saturation from North America and Europe is one of the major factors for the increasing demand for tourniquet devices. China was the largest market for tourniquets in Asia Pacific. Presence of large population suffering from orthopedic injuries in countries such as Japan, China, and India adds to the large patient pool. This in turn increases the number of tourniquet cuffs used in surgeries.
 The global tourniquet market exhibits intense competition among the existing players. The market is consolidated, characterized by the presence of few established companies. Major players operating in the global tourniquet market are Zimmer Biomet Holdings, Inc., Stryker Corporation, Delfi Medical Innovation, Inc., Hammarplast Medical AB, Pyng Medical Corporation, ulrich Medical, and VBM Medizintechnik GmbH.

Posted by at No comments:
Labels:

Wednesday 26 April 2017

Ophthalmic Lasers Market: Strategies & Insights, & Recent Developments

Lasers have become an essential part of treatment modality for a number of practicing ophthalmologist. Ophthalmic lasers have gained prominence with the popularity of laser-assisted surgeries for rectifying nearsightedness or myopia. The increasing incidence of ophthalmic disorders and rise in geriatric population in various regions have boosted the application of different types of lasers in treating specific eye problems and improving vision. Technological advances have significantly increased the safety and accuracy of these devices.
In recent years, vision scientists studying naturally occurring retinal fluorescence discovered newer applications in diagnostic retinal imaging Combined with advances in adaptive optics and the adoption of automation technologies, physicians find ophthalmic lasers helpful in detecting glaucoma, diabetic retinopathy, and several other devastating vision-stealing diseases in the early stages. All these developments are expected to catalyze the demand for ophthalmic lasers. Expanding at 4.60% CAGR from 2016 to 2024, the market is projected to reach US$1.44 bn by the end of forecast period.
 Obtain Report Details @
Which end users are expected to offer promising opportunities for vendors of ophthalmic lasers?
Hospitals, ophthalmic clinics, and ambulatory surgical centers (ASCs) have emerged as primary end users of this ophthalmic lasers. A major demand for ophthalmic laser surgeries is expected to come from various ophthalmic clinics and they are expected to contribute a significant chunk of market revenue in the coming years. The substantial demand for laser-assisted surgical processes, such as the LASIK surgery, among a large number of patients is attributed to the preference of eye specialists and the increased convenience witnessed by caretakers in clinical environments. Physicians seeking a non-invasive and accurate method for diagnosing Alzheimer’s in the earliest stages find the use of lasers as a promising prospect.
BioLight Israeli Life Sciences Investments Ltd., signed a memorandum of understanding with Chengdu Kanghong Pharmaceuticals Group Co., Ltd., a Chinese company, in April, 2017 to dilute its stake in IOPtima, IOPtima has been developing laser surgery technology for the treatment of glaucoma. Under the MoU, currently non-binding in nature, the Chinese company will invest a sum of $7 million in IOPtima for garnering 19% of its shares at a $30 million company value. This will confer on the company exclusive rights for selling ophthalmic lasers in China. Such developments bode well for the market. 
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20864
Which regions are anticipated to exhibit significant uptake of ophthalmic lasers?
North America is expected to provide lucrative avenues for the ophthalmic lasers market. The substantial demand for ophthalmic lasers is driven by the presence of a large number of leading companies in North America. The regional market occupied a significant market share of 40% in 2016. The spiraling investments of private players in research and development and the presence of a robust healthcare infrastructure are key factors fuelling the demand for ophthalmic lasers. In addition, a well-organized regulatory infrastructure that expedites the approval of new products are expected to boost product innovations, thereby catalyzing the regional market.
On the other hand, Asia Pacific is fast emerging as a prominent regional market for ophthalmic lasers. In the forthcoming years, the growth of the regional market is expected to outpace others. The prevalence of various vision disorders in various countries such as China and India is a key factor bolstering the demand for ophthalmic laser surgeries.
The Middle East and Africa (MEA) and Latin America are expected to provide exciting opportunities for player in the ophthalmic lasers market. The impressive growth is attributed to the soaring medical tourism and the inexpensive eye care treatments.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453

Posted by at No comments:
Labels:

Life Science Microscopy Devices Market Overview - Key Futuristic Trends And Competitive Landscape 2024

Over the past few years, microscopy devices have soared in popularity driven by their applications in studying various biological interactions and processes at cellular level. Their use have facilitated the discovery of novel therapies and advanced diagnostics in treating a wide variety of diseases worldwide. The need for advanced technologies to investigate various cell types and meticulously examine their interactions with other compounds has stimulated the demand for microscopy devices. An increasing number of biotechnology and pharmaceutical companies have shifted toward forming collaborations with contract research organizations (CRO) in order to leverage the potential of modern technical expertise and reduce the cost of R&D activities. This development has spurred the demand for microscopy devices in the life sciences industry.
Obtain Report Details @
In recent years, the advent of ultra-precision and high-resolution microscopy and increasing adoption of automation technologies in biosciences are key trends catalyzing the demand for microscopy devices in life sciences applications. The launch of fluorescence microscopes is an encouraging development in this regard. The worldwide market for life science microscopy devices is projected to reach US$2.0 bn by the end of the forecast period and is expected to rise at 6.5% CAGR of during 2016–2024.
Which are the microscopy device types likely to witness significant uptake in the life sciences industry?
The major types of microscopy devices used in life sciences applications are optical microscopes, electron microscopes, and scanning probe microscopes. Optical microscopes constitute a major segment in the market. The impressive demand for optical microscopes is attributed to their wide applications in research laboratories across various emerging nations and soaring demand in areas such as clinical, pathology, pharmacology and toxicology. The low cost of these devices is crucial factor bolstering their uptake. The development of integrated microscopes is also expected to fuel their demand. The prominence of integrated optical microscopes over electron and scanning probe microscopes is due to the cost-effectiveness of the former, as they do not need any additional systems such as detectors, scanners, and imaging.
The demand for optical microscopes is primarily fuelled by the growing popularity of fluorescence microscopes. The high sensitivity and specificity of fluorescence microscopes has led to their extensive use in a variety of intra and intercellular processes such as exocytosis and endocytosis. However, the prevalence of intense competition among vendors may slightly hamper the demand for optical microscopes in the forthcoming years.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4017
Which regions are projected to provide abundant promising opportunities for manufacturers of microscopy devices?
North America is expected to provide lucrative avenues for players in the life sciences microscopy devices market. The regional market held the dominant share in 2016 and is forecast to maintain its lead throughout the forecast period.  Spiraling R&D spending in the life sciences and biomedical industries is anticipated to bolster the demand for various types of microscopy in the region.
Meanwhile, the Asia Pacific market for microscopy devices in life sciences will exhibit a stellar performance along the forecast period. The substantial demand for microscopy devices in the region is on the account of rapid advances made in nanotechnology, especially in China and Japan, and continuous technological advancements in microscopy devices.
Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)